Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]
Discontinued
Reference number: GID-TA10512
The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer.
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.